section name header

Indications ⬇

REMS

Unlabeled Use:

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CNS: SUICIDAL THOUGHTS, ataxia, drowsiness, vertigo, excitement (↑ in children).

EENT: visual changes.

Resp: dyspnea.

CV: edema, orthostatic hypotension.

GI: anorexia, drug-induced hepatitis, nausea, vomiting.

Derm: alopecia, rash.

Hemat: blood dyscrasias, megaloblastic anemia.

Misc: folic acid deficiency.

Interactions ⬆ ⬇

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Mysoline

Action ⬆ ⬇

Therapeutic Effects:

Classifications ⬆ ⬇

Therapeutic Classification: anticonvulsants

Pharmacokinetics ⬆ ⬇

Absorption: 80–100% absorbed from the GI tract when administered orally.

Distribution: Widely distributed. Crosses the placenta and enters breast milk.

Metabolism/Excretion: Converted to phenobarbital and another active anticonvulsant compound (PEMA) by the liver.

Half-life: 3–7 hr.

Time/Action Profile ⬆ ⬇

(anticonvulsant effect)

ROUTEONSETPEAKDURATION
PO4–7 days7–10 days8–12 hr

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

PRI-mi-done audio

Code ⬆

NDC Code*